DiaMedica Therapeutics Inc. DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc.

DMAC

Rank in Stocks #12071
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical... DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.
Share Price
$9.33
Last synced: 2026-11-12
Market Cap
$503.29M
Change (1 day)
-3.42%
Change (1 year)
45.55%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Trade DiaMedica Therapeutics Inc. (DMAC)

Category

Healthcare
P/S ratio for DiaMedica Therapeutics Inc. (DMAC)
P/S ratio as of November 2026 TTM: 0.00
According to DiaMedica Therapeutics Inc.'s latest financial reports and stock price, its current price-to-sales ratio (TTM) is 0.00. At the end of 2025 the company had a P/S ratio of 0.00.
P/S ratio history for DiaMedica Therapeutics Inc. from 2004 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
2026 (TTM) 0.00 0.00%
2025 0.00 0.00%
2024 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 -100.00%
2018 45.07 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
2011 0.00 0.00%
2010 0.00 0.00%
2009 0.00 0.00%
2008 0.00 -100.00%
2007 205.19 -85.33%
2006 1.40K -0.23%
2005 1.40K -95.75%
2004 33.00K 0.00%
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
18.29 -
US
10.51 -
US
35.79 -
US
4.19 -
AU
6.63 -
BE

Questions about DiaMedica Therapeutics Inc.'s P/S ratio

What was DiaMedica Therapeutics Inc.'s P/S ratio in 2025?

In 2025, DiaMedica Therapeutics Inc.'s P/S ratio was 0.00, compared with 0.00 in 2024.

How has DiaMedica Therapeutics Inc.'s P/S ratio changed since 2020?

From 2020 to 2025, DiaMedica Therapeutics Inc.'s P/S ratio was highest in 2025 (0.00) and lowest in 2025 (0.00).

How does DiaMedica Therapeutics Inc.'s P/S ratio compare with similar companies?

DiaMedica Therapeutics Inc.'s P/S ratio (0.00) is lower than that of all 5 similar companies listed above. The highest among them is Moderna, Inc., with 35.79.